IBF
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
The Well-Funded ($50M) Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
SpliSense Secures $28.5 Million in Series B Financing
Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation participated in the round.
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22
Biond to receive $125 million upfront with more than $1 billion in potential development, regulatory, and sales milestones plus royalty payments for global rights to a novel immune checkpoint inhibitor.
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
The round was led by Israel Biotech Fund with participation from new investors, The Phoenix Insurance Company and Migdal Insurance Company, two of Israel’s leading institutional investors, and Biotel, as well as existing investors including Arkin Bio Ventures and Primera Capital.
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, announced today that the FDA has granted Fast Track designation for BST-236 for the treatment of acute myeloid leukemia (AML).